

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

ADVANCED MEDICAL TECHNOLOGY ASSN

2. Address:

1200 G ST NW #400, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

4. Contact Name: MEGAN M. IVORY

Telephone: 202-783-8700

E-mail (optional): mivory@advamed.org

Senate ID #: 17831-12

House ID #: 31001000

7. Client Name: Self

TYPE OF REPORT

8. Year 2004 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 2,360,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

h.r. 4766/s. 2803- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2005. (Bills making appropriations for the Food and Drug Administration, and related agencies for the fiscal year 2005.) H.R. 4818-Foreign Operations, Export Financing, and Related Programs Appropriations Act of 2005. (Bill as related to FDA funding, user fee calculations, trigger fix.)

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
HOUSE OF REPRESENTATIVES
SENATE
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAILEY, PAM
Covered Official Position (if applicable): N/A
Name: BAILEY, PAM
Covered Official Position (if applicable): N/A
Name: BAILEY, PAM
Covered Official Position (if applicable): N/A
Name: CHILDS, BLAIR
Covered Official Position (if applicable): N/A
Name: CHILDS, BLAIR
Covered Official Position (if applicable): N/A
Name: CHILDS, BLAIR
Covered Official Position (if applicable): N/A
Name: IVORY, MEGAN
Covered Official Position (if applicable): N/A
Name: IVORY, MEGAN
Covered Official Position (if applicable): N/A
Name: IVORY, MEGAN
Covered Official Position (if applicable): N/A
Name: KELLY, CAROL
Covered Official Position (if applicable): N/A
Name: KELLY, CAROL
Covered Official Position (if applicable): N/A
Name: KELLY, CAROL
Covered Official Position (if applicable): N/A
Name: TRUNZO, JANET
Covered Official Position (if applicable): N/A
Name: TRUNZO, JANET
Covered Official Position (if applicable): N/A
Name: TRUNZO, JANET
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

h.r. 4766/s. 2803- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2005. (Bills making appropriations for the Food and Drug Administration, and related agencies for the fiscal year 2005.) H.R. 4818-Foreign Operations, Export Financing, and Related Programs Appropriations Act of 2005. (Bill as related to FDA funding, user fee calculations, trigger fix.)

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
HOUSE OF REPRESENTATIVES
SENATE
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAILEY, PAM
Covered Official Position (if applicable): N/A
Name: BAILEY, PAM
Covered Official Position (if applicable): N/A
Name: BAILEY, PAM
Covered Official Position (if applicable): N/A
Name: CHILDS, BLAIR
Covered Official Position (if applicable): N/A
Name: CHILDS, BLAIR
Covered Official Position (if applicable): N/A
Name: CHILDS, BLAIR
Covered Official Position (if applicable): N/A
Name: IVORY, MEGAN
Covered Official Position (if applicable): N/A
Name: IVORY, MEGAN
Covered Official Position (if applicable): N/A
Name: IVORY, MEGAN
Covered Official Position (if applicable): N/A
Name: KELLY, CAROL
Covered Official Position (if applicable): N/A
Name: KELLY, CAROL
Covered Official Position (if applicable): N/A
Name: KELLY, CAROL
Covered Official Position (if applicable): N/A
Name: TRUNZO, JANET
Covered Official Position (if applicable): N/A
Name: TRUNZO, JANET
Covered Official Position (if applicable): N/A
Name: TRUNZO, JANET
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

P.L. 108-214-Medical Device Technical Corrections Act. (To make technical corrections relating to the amendments made by the Medical Device User Fee and Modernization Act of 2002 and to prohibit FDA from arbitrarily raising medical device user fees.) P.L. 108-276-Project BioShield Act of 2004. H.R. 2122-Project BioShield Act of 2003. (Public Law and bill to enhance research, development, and use of biomedical countermeasures to respond to public health threats affecting national security.) H.R. 663/S. 720-Patient Safety and Quality Improvement Act. (Bills to reduce the number of health care mistakes by defining a new voluntary medical error reporting system.) H.R. 4280/H.R. 5-Medical Malpractice Liability Limitation Bill (HEALTH) Act of 2004. S.11-Patients First Act of 2003. (Bills to improve patient access to health care services and provide improved medical care by reducing the excessive burden the liability system places on the health care delivery system.) S. 2061-Healthy Mothers and Healthy Babies Access to Care Act of 2003. S. 2207-Pregnancy and Trauma Care Access Protection Act of 2004. (Bills to improve women's health access to health care services and provide improved medical care by reducing the excessive burden the liability system places on the health care delivery system.) H. Con. Res. 324/S. Con. Res. 80-Concurrent Resolutions urging Japan to honor its commitments under the 1986 Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals, and for other purposes. (Concurrent Resolutions providing that medical technology has driven dynamic productivity gains, and related to trade issues including Japanese Foreign Reference Pricing.) H.R. 4842-United States-Morocco Free Trade Agreement Implementation Act (Bill to approve the U.S.-Morocco Free Trade Agreement entered into with the Government of Morocco, and the statement of administrative action proposed to implement the Agreement.) H.R. 4759-United States-Australia Free Trade Agreement. (Bill to implement the U.S.-Australia Free Trade Agreement.) H.R. 4281-Small Business Health Fairness Act of 2004. (Bill to improve access and choice of entrepreneurs with small businesses with respect to medical care for their employees.) S. 1570-The Fair Case for the Uninsured Act of 2003. (Bill to allow individuals a refundable credit against income tax purchase of private health insurance, and establish state health insurance safety net programs.) S. 2880-Medical Device Competition Act of 2004. (Bill to ensure free compensation in the medical device and hospital supply industries.) S. 2710-National Health Information Technology Adoption Act. (Bill to improve the quality and efficiency of health care delivery through improvements in health care information technology.) H.R. 463/S. 664-Investment in America Act of 2003. (Bills to permanently extend the research credit, to increase the rates of the alternative incremental credit, and to provide an alternative simplified credit for qualified research expenses.) H.R. 4555-Mammography Quality Standards Reauthorization Act of 2004. (Bill to revise and extend provisions relating to mammography quality standards.)

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE
U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAILEY, PAM
Covered Official Position (if applicable): N/A
Name: CHILDS, BLAIR
Covered Official Position (if applicable): N/A
Name: IVORY, MEGAN
Covered Official Position (if applicable): N/A
Name: KELLY, CAROL
Covered Official Position (if applicable): N/A
Name: TRUNZO, JANET
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ADVANCED MEDICAL TECHNOLOGY ASSN Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

P.L. 108-173-Medicare Prescription Drug, Improvement, and Modernization Act of 2003. (Public Law to provide for expeditious coverage of new medical devices and to strengthen and improve and modernize the Medicare program.) H.R. 4257/S. 2426-Critical Access to Clinical Lab Services Act of 2004. (Bills to clarify the treatment of payment under Medicare for clinical laboratory tests by critical access to hospitals.) H.R. 5252-Fair Access to Clinical Trials Act. (Bill to provide availability to the public of information on clinical trials to determine the safety and effectiveness of drugs, biological products, and devices, and for other purposes.) S. 2911-Medicare Competitive Acquisition Improvement Act of 2004. (Bill to make improvements in the Medicare competitive acquisition programs for certain items and services.) H.R. 5331/H.R. 4491-To Amend Part B of Title XVIII of the Social Security Act. (Bills to repeal the reduction in Medicare payment through competitive bidding for certain items of durable medical equipment.) S. 2493-Safe Importation of Medical Products and Other Rx Therapies Act of 2004. (Bill to protect the public health from the unsafe importation of medical products.)

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAILEY, PAM

Covered Official Position (if applicable): N/A

Name: FEDERICI, TARA M.

Covered Official Position (if applicable): N/A

Name: IVORY, MEGAN

Covered Official Position (if applicable): N/A

Name: KELLY, CAROL

Covered Official Position (if applicable): N/A

Name: LEE, TERESA

Covered Official Position (if applicable): N/A

Name: TRUNZO, JANET

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 11, 2005

Printed Name and Title: MEGAN M. IVORY - EXECUTIVE VICE PRESIDENT, FEDERAL GOVERNMENT AFFAI